SL
CPRX

Salomon & Ludwin’s Catalyst Pharmaceutical CPRX Stock Holding History

Salomon & Ludwin’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46.1K Buy
1,866
+1,093
+141% +$26K ﹤0.01% 523
2025
Q4 		$17.6K Sell
773
-175
-18% -$3.9K ﹤0.01% 1002
2025
Q3 		$19.8K Buy
+948
New +$19.5K ﹤0.01% 824

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Salomon & Ludwin's CPRX Position: Q1 2026 in Review

Salomon & Ludwin increased its Catalyst Pharmaceutical (CPRX) stake by 141% in Q1 2026, buying an estimated $26K and bringing the position to 1,866 shares worth $46.1K. The position accounts for ﹤0.01% of the portfolio, ranked #523.

Salomon & Ludwin first reported a position in CPRX in Q3 2025 and has held it in 3 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Salomon & Ludwin held 1,866 shares of Catalyst Pharmaceutical worth $46.1K as of Q1 2026.
  • Salomon & Ludwin bought 1,093 Catalyst Pharmaceutical shares in Q1 2026, an estimated $26K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Salomon & Ludwin's portfolio in Q1 2026, its #523 holding.
  • Salomon & Ludwin first reported a position in Catalyst Pharmaceutical in Q3 2025 and has held it in 3 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Salomon & Ludwin's 13F filing for Q1 2026, filed 11 May 2026.